Field Exclusivity Sample Clauses
The Field Exclusivity clause establishes that one party is granted exclusive rights to operate, sell, or provide services within a specific field or market segment. In practice, this means that the party receiving exclusivity is the only one permitted to engage in certain activities related to the defined field, and the granting party agrees not to authorize others to do the same within that scope. This clause is commonly used to protect investments, incentivize commitment, and prevent competition within the agreed-upon area, thereby ensuring the exclusive party can maximize the benefits of their efforts without interference.
Field Exclusivity. Subject to Bayer's continuing payment to Symyx of Research Expenses for a Field, Symyx will not conduct research in such Field for any third party or on its own behalf, during the Research Program Term, other than under this Agreement. During the period for which Bayer originally committed to make Research Funding Payments for a given Field (as set forth in this Agreement for Initial Fields and as agreed by the parties for any additional Fields), Symyx will give Bayer thirty (30) days written notice in the event exclusivity set forth in this Section 2.5 no longer applies for such Field due to Bayer discontinuing payment, and on request of Bayer, the parties will discuss what payments, if any, are needed to maintain exclusivity; provided, however, that Symyx shall not be required to provide such notice to Bayer if the parties have agreed in writing that the exclusivity set forth in this Section 2.5 no longer applies for such Field.
Field Exclusivity. 2.5.1 During the term of this Agreement, PACKARD shall have the right to sell, and have sold, all versions of Oasis LabCard chips [ * ] for use with Systems in the Field or for use with Third Party Instrumentation in the Field. So long as PACKARD continues to satisfy the Due Diligence Requirements described below, the foregoing right to sell, and have sold, all versions of Oasis LabCard chips [ * ] for use with Systems in the Field or for use with Third Party Instrumentation in the Field shall be exclusive to PACKARD. For purposes of this Section 2.5.1, PACKARD shall be deemed to have satisfied the "Diligence Requirement" during any period if (1) PACKARD is diligent in promoting, distributing and selling Oasis LabCard chips, and (2) PACKARD is demonstrably committed to selling Oasis LabCard chips for use with Third Party Instrumentation as well as for use with Instruments manufactured by PACKARD. During the [ * ] period following the first commercial sale of a System to a third party, diligence shall be determined based on actual sales, reasonable penetration into the Homogenous Assay market for the Field, and the number of and volume [*] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Field Exclusivity. Unless otherwise agreed in writing, Jack▇▇▇ ▇▇▇ll only allow Argonaut Field exclusive distribution rights for Products.
Field Exclusivity. 5.1 Neither AccuMed nor any Subsidiary shall develop, manufacture, purchase, distribute, or market anywhere worldwide during the term of this Agreement (or have or enter into any agreement or arrangement with respect to) any product or system: (i) competitive with or substantially similar to the Imaging System or Software Products or (ii) in the Field.
5.2 Termination of Field Exclusivity shall have no effect on Product Exclusivity under the licenses granted to Ventana under Article 2.
Field Exclusivity. Until the earlier of (a) [***] after the termination of the Research Program Term, if such termination occurs before [***] of the Effective Date, or (b) [***] after the end of the Research Program Term, Pharmacopeia will not (i) knowingly make compounds or combinatorial libraries for any third person or entity specifically for screening any target in the Field actually screened in the Research Program, (ii) perform contract screening for any third person or entity with respect to any target in the Field actually screened in the Research Program, or (iii) perform for its own account any screening with respect to any target in the Field actually screened in the Research Program. Organon understands that in the ordinary course of its business Pharmacopeia provides libraries to third parties for screening against unidentified targets.
Field Exclusivity. Neither Party, absent the Parties’ mutual written agreement, [***]. For clarity, each Party agrees, on its own behalf and on behalf of its Affiliates, not to (and shall cause its Affiliates not to) [***] with respect to [***] is permitted under this Agreement, but such other Party may not [***] (absent the Parties’ mutual written agreement); provided that the results of such Research conducted during the Research Term [***] on a Calendar Quarter basis during the performance of such Research and will be deemed to be Jointly-Owned Collaboration IP created during the Research Activities except to the extent that any such results are subject to Section 10.2.1(a)(iii) or 10.2.2(a)(ii); provided, further, that [***]. In the event a Party desires to Develop or Commercialize [***], prior to any Development or Commercialization thereof, (a) such Party shall [***] and (b) both Parties shall [***]. In addition, and without limiting the foregoing or any license grant to Lilly under Section 2.1, [***] may not (except as specifically permitted under this Agreement) (i) [***] or (ii) [***], in each case (clauses (i) or (ii)), that [***].